Raises 2027 combined sales outlook for Skyrizi and Rinvoq to more than $27B; Raises peak sales outlook for Ubrelvy and Qulipta to more than $3B combined.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABBV:
- Options Volatility and Implied Earnings Moves Today, February 02, 2024
- U.S. sends offers for drugs selected for price negotiations, NY Times says
- ABBV Earnings this Week: How Will it Perform?
- Palo Alto downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- AbbVie upgraded to Outperform on growth confidence at William Blair